Radius: A Phase 2 Randomized Trial Investigating Standard of Care ± Midostaurin after Allogeneic Stem Cell Transplant in FLT3 -ITD–Mutated AML

米多司他林 医学 内科学 肿瘤科 移植 Fms样酪氨酸激酶3 癌症研究 帕纳替尼 索拉非尼 胃肠病学 造血干细胞移植 髓系白血病 白血病 无进展生存期 养生
作者
Richard T. Maziarz,Mrinal M. Patnaik,Bart L. Scott,Sanjay R. Mohan,Abhinav Deol,Scott D. Rowley,Dennis Dong Hwan Kim,Kelly Haines,Gaetano Bonifacio,Patrice Rine,Das Purkayastha,Hugo F. Fernandez
出处
期刊:Blood [Elsevier BV]
卷期号:132: 662-662 被引量:49
标识
DOI:10.1182/blood-2018-99-113582
摘要

Abstract Introduction: Midostaurin, a multitargeted tyrosine kinase inhibitor (TKI), plus induction and consolidation chemotherapy followed by single-agent midostaurin maintenance therapy resulted in significant benefits in event-free and overall survival (OS) in adults with newly diagnosed FLT3-mutated acute myeloid leukemia (AML) compared with placebo (RATIFY study; Stone et al, N Engl J Med, 2017). In RATIFY, patients who received allogeneic hematopoietic stem cell transplant (alloSCT) did not receive midostaurin maintenance. Despite alloSCT providing the highest likelihood of sustained remission, relapse rates remain high (30%-59%; Schiller et al, Biol Blood Marrow Transplant, 2016), especially in patients with FLT3-internal tandem duplication-positive (ITD+) AML. Posttransplant maintenance therapy may improve this outcome. Here, we report the primary results from RADIUS, a randomized, open-label, phase 2 exploratory trial (NCT01883362) that investigated whether the addition of midostaurin to standard of care (SOC) after alloSCT could reduce the risk of relapse in patients with FLT3-ITD+ AML. Methods: Adults (aged 18-70 y) who had undergone myeloablative alloSCT in first complete remission (CR1), had achieved hematologic recovery, and were transfusion independent were eligible. Patients enrolled postengraftment and were randomized to receive SOC with or without midostaurin 50 mg twice daily continuously (4-week cycles) for up to 12 cycles. Study treatment started 28 to 60 days post-alloSCT and patients were followed for ≥24 months post-alloSCT. The primary endpoint was relapse-free survival (RFS) at 18 months post-alloSCT. Secondary endpoints included safety and disease-free survival (DFS), OS, and RFS at 24 months post-alloSCT. The study was not adequately powered to detect a statistical difference between the 2 arms; a sample size of 60 was calculated to detect a 50% reduction in the risk of relapse. Results: 60 patients were randomized (30 per arm). Baseline characteristics were generally balanced between the 2 arms. Overall, 30 patients completed 12 cycles of study treatment (14 with SOC; 16 with midostaurin). The median exposure to midostaurin was 10.5 months (range, 0.2 to 12.0 months) and the median dose intensity was 93 mg/day (range, 15-100 mg/day). Early treatment discontinuations were similar between arms (15 in the SOC arm; 13 in the midostaurin arm), frequently due to adverse events (AEs; 3% vs 23%) and consent withdrawal (20% vs 7%). Among 6 patients who withdrew consent in the SOC arm, 2 did so to pursue other TKI therapies. Midostaurin dose modifications occurred in 19 patients (63%), mostly due to AEs (84%); 1 instance was due to receiving a concomitant CYP3A4 inhibitor. With an estimated 18-month RFS (95% CI) of 76% (54%-88%) in the SOC arm and 89% (69%-96%) in the midostaurin arm, estimated relapse rates were 24% and 11%, respectively, which is a 46% relative reduction in the risk of relapse with the addition of midostaurin (Figure 1). At 18 months, the median RFS was not reached in either arm. Longer follow-up at 24 months (data not yet matured) will be presented, including RFS, OS, and DFS. In the SOC and midostaurin arms, AEs were reported in 87% and 100% of patients, respectively (the most common any-grade AE was vomiting: 23% vs 73%; Figure 2); serious AEs were reported in 57% and 30% of patients, respectively, with diarrhea (7% vs 13%), nausea (10% vs 3%), vomiting (10% vs 3%), and pyrexia (7% vs 7%) being the most common. Overall, 8 patients discontinued midostaurin therapy due to AEs (mostly gastrointestinal related) and 12 died on study (all during the follow-up phase; 8 in the SOC arm and 4 in the midostaurin arm [n=4 vs n=2 due to AML disease progression]). Rates of graft-vs-host disease (GVHD) were generally similar between the SOC and midostaurin arms (overall, 70% vs 73%; acute GVHD, 53% vs 57% [grade 2/3 events: 37% vs 30%; no grade 4 events]; chronic GVHD, 47% vs 37% [most events were mild or moderate; severe events: 1 with SOC and 2 with midostaurin]). Conclusions: Adding midostaurin to SOC reduced the risk of relapse at 18 months post-alloSCT by 46% (vs SOC). The safety profile of single-agent midostaurin was consistent with previous reports; no major safety concerns were identified when adding midostaurin to SOC following alloSCT. These data suggest that midostaurin monotherapy can be safely administered for ≤1 year and may improve outcomes in patients who undergo alloSCT in CR1. Disclosures Maziarz: Novartis Pharmaceuticals Corporation: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Incyte: Consultancy, Honoraria; Juno Therapeutics: Consultancy, Honoraria; Kite Therapeutics: Honoraria; Athersys, Inc.: Patents & Royalties. Scott: Agios: Consultancy; Novartis: Research Funding; Celgene: Consultancy, Research Funding; Alexion: Consultancy. Deol: Kite Pharmaceuticals: Consultancy; Novartis: Consultancy. Kim: Novartis: Consultancy, Honoraria, Research Funding; Briston-Meyers Squibb: Consultancy, Honoraria, Research Funding; Paladin: Consultancy; Pfizer: Consultancy. Haines: Novartis: Employment. Bonifacio: Novartis: Employment. Rine: Novartis: Employment. Purkayastha: Novartis Pharmaceuticals Corporation: Employment.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
普鲁卡因发布了新的文献求助10
2秒前
加油杨完成签到 ,获得积分10
3秒前
liuyanq发布了新的文献求助10
6秒前
随风完成签到,获得积分10
9秒前
量子星尘发布了新的文献求助10
11秒前
米九完成签到,获得积分10
13秒前
zhao完成签到,获得积分10
16秒前
普鲁卡因发布了新的文献求助10
16秒前
zj完成签到,获得积分10
22秒前
蓝橙完成签到,获得积分10
23秒前
27秒前
GD88完成签到,获得积分10
28秒前
糟糕的梨愁完成签到,获得积分10
29秒前
莫西莫西完成签到 ,获得积分10
30秒前
小趴蔡完成签到 ,获得积分10
32秒前
唐唐发布了新的文献求助10
32秒前
飘逸剑身完成签到,获得积分10
35秒前
airtermis完成签到 ,获得积分10
35秒前
gfasdjsjdsjd完成签到,获得积分10
36秒前
36秒前
杨宁完成签到 ,获得积分10
36秒前
MchemG应助transition采纳,获得20
37秒前
科研通AI2S应助科研通管家采纳,获得10
38秒前
lxy发布了新的文献求助10
40秒前
gfasdjsjdsjd发布了新的文献求助10
41秒前
JCao727完成签到,获得积分10
41秒前
41秒前
42秒前
OAHCIL完成签到 ,获得积分10
43秒前
lixueao发布了新的文献求助10
44秒前
无辜的行云完成签到 ,获得积分0
47秒前
FIN应助gfasdjsjdsjd采纳,获得20
49秒前
今后应助gfasdjsjdsjd采纳,获得10
49秒前
排骨炖豆角完成签到 ,获得积分10
51秒前
一叶知秋应助大橙子采纳,获得10
53秒前
kk完成签到,获得积分10
56秒前
敏感春天完成签到,获得积分10
56秒前
凶狠的期待完成签到,获得积分10
58秒前
自然函发布了新的文献求助30
58秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038128
求助须知:如何正确求助?哪些是违规求助? 3575831
关于积分的说明 11373827
捐赠科研通 3305610
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022